Key result
A review of available literature highlights the need for a personalized approach to prescribing direct oral anticoagulants based on patient pharmacogenetic characteristics to reduce complication risks.
Why the study?
Reducing the risk of direct oral anticoagulant complications based on genetic characteristics remains controversial, highlighting the need for a personalized approach.
Does pharmacogenetic testing improve the efficacy and safety of direct oral anticoagulants in patients with hypercoagulation?
Does pharmacogenetic testing improve the efficacy and safety of direct oral anticoagulants in patients with hypercoagulation?
This review highlights the potential importance of pharmacogenetic testing to personalize DOAC therapy and reduce complication risks, emphasizing the need for further research.
Answers are grounded in this paper and cite their sources.
Should not yet change DOAC prescribing; hypothesis-generating for pharmacogenetic personalization pending randomized trials.
Despite the proven efficacy and relative safety of direct oral anticoagulants (DOAC), the issue of reducing the risk of complications associated with their use, depending on the genetic characteristics of patients, remains controversial. A personalized approach to the selection of DOAC should be developed. In this article, we review the available information on the feasibility of prescribing DOAC to patients with various diseases associated with hypercoagulation and on pharmacogenetic aspects of the DOAC application. The need for further research is substantiated, along with the importance of a wider introduction of the molecular-biological analysis of gene polymorphisms, whose presence affects the efficacy and safety of these drugs. In the course of the work, publications from the MedScape, PubMed, and eLIBRARY databases were analyzed.
No takes yet. Share an insight, caveat, or question.
Ганцгорн et al. (2023) conducted a review in Diseases associated with hypercoagulation. Direct oral anticoagulants (DOAC) was evaluated. A review of available literature highlights the need for a personalized approach to prescribing direct oral anticoagulants based on patient pharmacogenetic characteristics to reduce complication risks.
Synapse has enriched 10 related papers. Consider them for comparative context: